Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters
暂无分享,去创建一个
Vivian Hook | Charles Mosier | Charles Mosier | Lydiane Funkelstein | Thomas Toneff | Armen Abagyan | Michael Ziegler | Lydiane Funkelstein | V. Hook | T. Toneff | M. Ziegler | Armen Abagyan
[1] A. D. Smith,et al. A simple method for the isolation of adrenal chromaffin granules on a large scale. , 1967, The Biochemical journal.
[2] Roberto Cappai,et al. Metals and amyloid‐β in Alzheimer's disease , 2005, International journal of experimental pathology.
[3] D. O'Connor,et al. Primary culture of bovine chromaffin cells , 2007, Nature Protocols.
[4] Jee Hoon Roh,et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.
[5] P. Wong,et al. The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential , 2009, The Journal of Neuroscience.
[6] P. Fraser,et al. The β-Secretase-Derived C-Terminal Fragment of βAPP, C99, But Not Aβ, Is a Key Contributor to Early Intraneuronal Lesions in Triple-Transgenic Mouse Hippocampus , 2012, The Journal of Neuroscience.
[7] D. Selkoe,et al. The Transmembrane Aspartates in Presenilin 1 and 2 Are Obligatory for γ-Secretase Activity and Amyloid β-Protein Generation* , 2000, The Journal of Biological Chemistry.
[8] Xiongwei Zhu,et al. Probing and trapping a sensitive conformation: amyloid-β fibrils, oligomers, and dimers. , 2012, Journal of Alzheimer's disease : JAD.
[9] T. Shibasaki,et al. Roles of cAMP signalling in insulin granule exocytosis , 2009, Diabetes, obesity & metabolism.
[10] J. Fujita-Yoshigaki. Divergence and convergence in regulated exocytosis: the characteristics of cAMP-dependent enzyme secretion of parotid salivary acinar cells. , 1998, Cellular signalling.
[11] Katalin F Medzihradszky,et al. Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease , 2005, Biological chemistry.
[12] J. Growdon,et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.
[13] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[14] F. Fahrenholz,et al. Over-expression of two different forms of the α-secretase ADAM10 affects learning and memory in mice , 2006, Behavioural Brain Research.
[15] S. Sisodia. Alzheimer's disease: perspectives for the new millennium. , 1999, The Journal of clinical investigation.
[16] Patty C. Kandalepas,et al. Identification and biology of β‐secretase , 2012, Journal of neurochemistry.
[17] D. Borchelt,et al. Endoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo , 1996, Neuron.
[18] S W Carmichael,et al. The adrenal chromaffin cell. , 1985, Scientific American.
[19] D. O'Connor,et al. Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication. , 2010, Journal of proteome research.
[20] N. Robakis,et al. Release of nontransmembrane full-length Alzheimer's amyloid precursor protein from the lumenar surface of chromaffin granule membranes. , 1998, Biochemistry.
[21] Michael S. Wolfe,et al. γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] D. Njus,et al. The chromaffin vesicle: a model secretory organelle. , 1985, The Physiologist.
[23] N. Robakis,et al. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[24] Hong Wang,et al. PEN-2 and APH-1 Coordinately Regulate Proteolytic Processing of Presenilin 1* , 2003, The Journal of Biological Chemistry.
[25] William Arbuthnot Sir Lane,et al. Proteomics of neuroendocrine secretory vesicles reveal distinct functional systems for biosynthesis and exocytosis of peptide hormones and neurotransmitters. , 2007, Journal of proteome research.
[26] F. Sala,et al. Nicotinic acetylcholine receptors of adrenal chromaffin cells , 2007, Acta physiologica.
[27] W. Huttner,et al. Chromogranin B Gene Ablation Reduces the Catecholamine Cargo and Decelerates Exocytosis in Chromaffin Secretory Vesicles , 2010, The Journal of Neuroscience.
[28] J. Witton,et al. The functional neurophysiology of the amyloid precursor protein (APP) processing pathway , 2010, Neuropharmacology.
[29] Kyong-Tai Kim,et al. Short-term plasticity of small synaptic vesicle (SSV) and large dense-core vesicle (LDCV) exocytosis. , 2009, Cellular signalling.
[30] D. Brenneman,et al. Cathepsins B and L Differentially Regulate Amyloid Precursor Protein Processing , 2009, Journal of Pharmacology and Experimental Therapeutics.
[31] Blaine R. Roberts,et al. The role of metallobiology and amyloid‐β peptides in Alzheimer’s disease , 2012, Journal of neurochemistry.
[32] Hongqiao Li,et al. Mammalian APH-1 Interacts with Presenilin and Nicastrin and Is Required for Intramembrane Proteolysis of Amyloid-β Precursor Protein and Notch* , 2002, The Journal of Biological Chemistry.
[33] S. Yasothornsrikul,et al. Arginine and Lysine Aminopeptidase Activities in Chromaffin Granules of Bovine Adrenal Medulla: Relevance to Prohormone Processing , 1998, Journal of neurochemistry.
[34] J. Growdon,et al. Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Kindy,et al. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence. , 2012, Journal of Alzheimer's disease : JAD.
[36] M. Bogyo,et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[37] E. Masliah,et al. Molecular mechanisms of neurodegeneration in Alzheimer's disease. , 2010, Human molecular genetics.
[38] N. Robakis,et al. Full‐Length and Truncated Alzheimer Amyloid Precursors in Chromaffin Granules: Solubilization of Membrane Amyloid Precursor Is Mediated by an Enzymatic Mechanism , 1995, Journal of neurochemistry.
[39] P. S. St George-Hyslop,et al. Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid β42 from Isolated Intact Nerve Terminals , 2010, The Journal of Neuroscience.
[40] R. Malinow,et al. APP Processing and Synaptic Function , 2003, Neuron.
[41] D. O'Connor,et al. The Catecholamine Release-Inhibitory “Catestatin” Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses , 2004, Molecular Pharmacology.
[42] N. Greig,et al. Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid-β Levels , 2013, PloS one.
[43] V. Vingtdeux,et al. Identification and biology of α‐secretase , 2012, Journal of neurochemistry.
[44] Virginia M. Y. Lee,et al. Regulation of Amyloid Precursor Protein Secretion by Glutamate Receptors in Human Ntera 2 Neurons (NT2N)* , 1998, The Journal of Biological Chemistry.
[45] L. Mucke,et al. Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.
[46] J. Daly,et al. Structure-activity relationships for activation of adenylate cyclase by the diterpene forskolin and its derivatives. , 1983, Journal of medicinal chemistry.
[47] C. Peters,et al. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. , 2009, Biochemical and biophysical research communications.
[48] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[49] B. Strooper,et al. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.
[50] B. Kennedy,et al. A sensitive radioenzymatic assay for epinephrine forming enzymes. , 1988, Life sciences.
[51] D. Holtzman,et al. Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide , 2012, The Journal of Neuroscience.
[52] D. O'Connor,et al. The Protein Architecture of Human Secretory Vesicles Reveals Differential Regulation of Signaling Molecule Secretion by Protein Kinases , 2012, PloS one.
[53] P. Reddy,et al. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. , 2011, Biochimica et biophysica acta.
[54] D. O'Connor,et al. Human Cathepsin V Protease Participates in Production of Enkephalin and NPY Neuropeptide Neurotransmitters* , 2012, The Journal of Biological Chemistry.
[55] H. Lodish. Molecular Cell Biology , 1986 .
[56] D. Selkoe,et al. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.
[57] M. Feany,et al. Why size matters – balancing mitochondrial dynamics in Alzheimer's disease , 2013, Trends in Neurosciences.
[58] J. Crawley,et al. Galanin impairs performance on learning and memory tasks: Findings from galanin transgenic and GAL-R1 knockout mice , 2005, Neuropeptides.
[59] C. Westmark. What’s hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders , 2013, Molecular Psychiatry.
[60] J. Buxbaum,et al. Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease , 2003, Alzheimer disease and associated disorders.
[61] J. Ghiso,et al. SDS-PAGE/immunoblot detection of Abeta multimers in human cortical tissue homogenates using antigen-epitope retrieval. , 2010, Journal of visualized experiments : JoVE.
[62] R. Kelly,et al. Constitutive and regulated secretion of proteins. , 1987, Annual review of cell biology.
[63] E. Godaux,et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.
[64] Jill L. Wegrzyn,et al. Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. , 2008, Annual review of pharmacology and toxicology.
[65] E. Kremmer,et al. ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons , 2010, The EMBO journal.
[66] J. Hohmann,et al. Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.